Rafael Holdings

Rafael Holdings

Pharmaceuticals
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.

$100.9M

Market Cap • 9/25/2026

2017

(9 years)

Founded

2018

(8 years ago)

IPO

NYSE

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

1,3

P/S

102,9

P/E

—

BVPS

1,5

EPS

—

Market Cap

Market Cap

100,9M

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-24,6%

Total Yield

-24,6%

Payout

0%

Retained Earnings

-252,7M

Profitability

Gross Margin

95,1%

Net Margin

—

ROE

—

ROA

—

Growth

CAGR Revenue 5Y

-25,4%

CAGR Net Income 5Y

16,8%

CAGR EPS 5Y

-8,8%

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium